©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF APPLIED SCIENCES 11(1):83-88, 2026 ISSN: 2550-7931

https://doi.org/10.59298/IDOSRJAS/2026/1118388 IDOSRJAS11106

Diabetes and Obesity: Mechanistic Insights

Wambui Kibibi J.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Obesity and type 2 diabetes (T2D) are interrelated global health challenges with rising prevalence and profound socioeconomic impact. Central adiposity is a key driver of metabolic dysfunction, contributing to insulin resistance, β-cell stress, and dysregulated energy homeostasis. Adipose tissue functions as an active endocrine organ, secreting adipokines, lipokines, and inflammatory mediators that influence systemic metabolism and promote T2D development. Mechanistic pathways linking obesity to T2D include chronic inflammation, ectopic fat deposition, lipotoxicity, mitochondrial dysfunction, gut microbiome alterations, and dysregulated neural and hormonal control of appetite and glucose homeostasis. Genetic, epigenetic, and developmental factors further modulate individual susceptibility. Understanding these complex interactions provides a basis for translational interventions targeting metabolic pathways, adipose tissue function, and energy balance to prevent or delay T2D onset. Future research should focus on identifying precise biomarkers, elucidating multi-organ crosstalk, and developing interventions that mitigate metabolic dysfunction independent of weight loss.

Keywords: Obesity**,** Type 2 diabetes**,** Insulin resistance**,** Adipokines and Metabolic dysregulation.

INTRODUCTION

Globally, the prevalence of obesity and type 2 diabetes (T2D) is rising at alarming rates, posing substantial health and economic burdens. Individuals with obesity exhibit an increased risk of developing T2D, while in the majority of patients with T2D, obesity is a predominant risk factor [1]. Central adiposity, in particular, plays a crucial role in the pathogenesis of T2D by disrupting metabolism and insulin action in peripheral tissues. The understanding of how excess body fat is linked to the development of T2D remains incomplete. There is significant heterogeneity in glucose metabolism in obese individuals [2]. Studies indicate that in many overweight people, increased body fat does not lead to diabetes; whereas severe insulin resistance and progressive β-cell dysfunction are observed in a subset of obese individuals who develop T2D. Well-established insulin resistance and β-cell dysfunction in T2D suggest prioritization on elucidating mechanisms linking adiposity to these two abnormalities and thereby acquiring knowledge for developing effective interventions. Obesity and T2D are increasing in prevalence, resulting in major health and socioeconomic consequences [1]. The relationships between these disorders are well established, but some underlying mechanisms and bidirectional links are not fully understood. Pancreatic β cells and adipose tissue are closely interconnected through bioactive hormones and signaling pathways. The gut microbiome may also play a key role in mediating the dialogue between adipocytes and β cells, with potential therapeutic strategies. Additional players such as skeletal muscle and the liver may be involved in this metabolic crosstalk [2]. Future research should focus on developing therapeutic approaches targeting the gut microbiota and dysfunctional metabolic pathways, supported by clinical studies to clarify the roles of the microbiome and metabolites in this complex interaction [1].

Conceptual Frameworks Linking Diabetes and Obesity

Adiposity, obesity, and type 2 diabetes are tightly interrelated conditions. Evidence for linkage pervades the literature, but a unified view of the relationships remains elusive [2]. Models of obesity-driven diabetes emphasize

adiposity as a primary driver; alternative frameworks propose obesity as a catalyst or risk factor acting through inflammation, gut dysbiosis, endocannabinoids, or similar avenues [4]. Obesity and type 2 diabetes share multiple clinical features and common risk factors. Insulin resistance and beta-cell stress constitute core pathophysiological mechanisms linking these conditions [7]. Their interdependence is even more pronounced in metabolic syndrome, which includes abdominal obesity, dyslipidemia, and hypertension among its principal components. Over one-third of recipients of the new type 2 diabetes diagnosis have a body mass index below the obesity threshold, underscoring the need for a broader perspective [3, 1].

Adipose Tissue as an Active Endocrine Organ

Adipose tissue is an active endocrine organ that actively releases a variety of factors within the circulation. Within the circulatory system, these bioactive molecules exert systemic functions and contribute to the regulation of energy and glucose metabolism [4]. The active release of these factors creates a potential for dysfunction to trigger systemic abnormalities associated with metabolic diseases such as obesity and type 2 diabetes. Over forty adipocyte-derived substances commonly referred to as adipokines, as well as free fatty acids and lipid-derived metabolites (lipokines) have been described [5]. Through these mediators, adipose tissues influence a wide spectrum of metabolic processes involving blood glucose homeostasis, lipid storage and release, and energy expenditure. Other systems that regulate metabolism, including the endocrine pancreas, the liver, and muscle, are also impacted [8]. These factors are released differentially at the tissue level depending on their anatomical localization, the type of tissue (white, brown, and beige), and the state of metabolic health. Apart from classical adipokines and free fatty acids, various other extracellular signal molecules and metabolites produced by adipose tissues regulate systemic energy metabolism [9]. Recent findings further indicate that the secretory capacity of adipose tissues and the subsequent endocrine outputs are closely linked to the structural and vascular remodelling of adipose tissue triggered by excessive nutrient intake. Adipocyte hypertrophy, changes in the density of tissue capillaries, and the infiltration of immune cells into adipose depots take place early in the development of obesity. Such remodelling shifts the composition of adipokines towards an increase in factors with deleterious effects on systemic metabolism [8]. In particular, inflammation-related factors produced by both adipocytes and resident immune cells alter metabolic homeostasis and promote the development of insulin resistance [2]. Other tissue-intrinsic properties, such as adipocyte size and shape, polarisation of macrophages associated with angiogenic activity, and local release of cytokines and lipid metabolites, also modulate the endocrine function of adipose tissues, influencing systemic metabolism [9].

Insulin Resistance: Molecular Pathways and Contributing Factors

Insulin resistance represents a core defect in the progression of metabolic diseases, particularly type 2 diabetes [6]. In liver and muscle, insulin resistance derives from failure to activate downstream glucose disposal pathways, whereas in β-cells it refers to impaired stimulation of insulin secretion through multiple complementary signaling routes [3]. Obesity elevates the risk for type 2 diabetes and other metabolic disorders through insulin resistance and β-cell failure; as such, deeper knowledge of insulin resistance is essential for comprehending the pathogenesis of diabetes and for developing effective preventive and therapeutic strategies [5]. Several parallel routes contributing to insulin resistance have been identified [6]. These can be classified broadly as either canonical or noncanonical and encompass diverse mediators, notably free fatty acids, diacylglycerols, inflammatory cytokines, tumor necrosis factor α, various adipokines, and gut-derived molecules such as bacterial lipopolysaccharide. In the context of obesity and diabetes, inflammation, lipotoxicity and alterations in acquired endocrine programming are particularly relevant [5]. In addition to the above systemic pathways, factors such as endoplasmic reticulum and mitochondrial dysfunction, the gut microbiome and neurohormonal signals are all relevant to insulin resistance and β-cell failure. Obesity-induced changes to any of these systems can therefore influence the degree of insulin resistance and consequently β-cell demand [5].

Inflammation and Immune Cell Infiltration

The activation of inflammatory pathways in white adipose tissue and consequent infiltration of immune cells are critical events in the metabolic dysfunction associated with obesity, linking excess fat accumulation to insulin resistance and β-cell impairment [7]. An inflammatory response is also set off in non-adipose tissues such as the liver and pancreas [8]. Aggravating these aerobic processes, alterations in immune-cell dynamics—including a raised abundance of pro-inflammatory cell types, like M1 macrophages and dendritic cells—occur throughout the body; immune mediators released by these cells, notably TNF and IL-6, further affect metabolic homeostasis. While the impact of inflammation on diabetes pathogenesis has long been acknowledged, substantial questions remain about which particular components of inflammation drive metabolic disturbances in obesity and the timing of these events relative to changes in nutrient homeostasis [5]. Adipocytes, having been long attributed an inert role in the immune system, are now recognized to play an active part in maintaining metabolic health through the

secretion of a diverse range of signaling molecules[6]. Excess caloric intake and fat accumulation in pre-obese states modify the transcriptional profiles and secretory programs of both adipocytes and other cells of the adipose tapestry, including endothelial cells and macrophages; the resultant alteration of the adipose secretome in dangerously overweight individuals contributes to system-wide and tissue-specific metabolic disturbances. The mechanistic basis of metabolically triggered inflammation remains an area of active investigation, offering a range of potential targets for therapeutic intervention [9].

Lipotoxicity and Ectopic Fat Deposition

Excessive fat accumulation leads to ectopic fat deposition within liver, muscle, pancreatic islets, heart, and other organs with significant metabolic consequences [10]. Fat accumulation in these sites is associated with obesity and metabolic disorders, whereas adipose tissue hypertrophy is linked with type 2 diabetes. Consequently, ectopic fat deposition is relevant to the progression from obesity to type 2 diabetes, providing significant insights into the links among obesity, diabetes, and lipid metabolism [11]. Abnormal accumulation of lipids in tissues outside their physiological storage depots contributes to a number of metabolic diseases. Ectopic fat accumulation can occur in response to excess energy intake, increased de novo lipogenesis, and accelerated lipolysis from white adipose tissue, leading to insulin resistance and type 2 diabetes [14].

Adipokines and Their Roles in Metabolic Regulation

Adipose tissue is considered an endocrine organ that secretes several factors known as adipokines, which exert systemic effects on metabolism, insulin action, and appetite regulation [6]. The main adipokines that exert regulatory effects on metabolism are leptin, adiponectin, visfatin, retinol-binding protein [4], and resistin 12. Factors like vascular remodeling, changes in immune system cell composition, monocyte infiltration, and modifications in the population of macrophages also contribute to metabolic regulation by adipose tissue [5]. The functions and pathophysiological roles of these factors have been extensively examined, leading to the identification of those that can be selectively targeted for therapeutic intervention [11]. The development of obesity is accompanied by alterations of adipokine expression that can profoundly affect metabolic homeostasis and contribute to the development of insulin resistance. In obesity, the secretion of the adipokine leptin is increased, while the amounts of the anti-diabetic adipokine adiponectin are diminished, facilitating the progression of metabolic disorders [13].

Beta-Cell Dysfunction and Pancreatic Adaptations

Obesity and type 2 diabetes are characterized by excessive accumulation of fat in multiple organs including the liver, muscle, and pancreas, leading to metabolic dysregulation and insulin resistance [13]. The excessive accumulation of nutrients in these tissues results in beta-cell dysfunction through glucolipotoxicity[16]. Initiated by an increase in beta-cell workload, hyperplasia occurs at early obesity stages; however, when beta-cell stress persists, cellular integrity is gradually lost and hyperplasia ceases [15]. Eventually, the pancreas undergoes adaptive and maladaptive changes, some attempt to compensate for the deterioration of metabolic control, while the others contribute to the progression of the disease to advanced overt diabetes [14].

Mitochondrial Dynamics and Energy Homeostasis in Obesity-Related Diabetes

Mitochondrial dynamics regulate cellular energy homeostasis, impacting the development of obesity-related diabetes through mechanisms that remain incompletely understood [11]. Mitochondrial dysfunction correlates with increased oxidative stress, metabolic inflexibility, and insulin resistance. Factors that alter mitochondrial dynamics and the associated metabolic reprogramming of peripheral tissues are under investigation as contributors to insulin-resistance syndromes [14]. Obesity also disrupts mitochondrial dynamics, and irregularities in mitophagy and mitochondrial quality control are observed in beta cells and peripheral tissues from insulin-resistant and diabetic individuals. Impaired transport of fatty-acid–derived metabolites into mitochondria leads to incomplete oxidation of fatty-acid substrates and may link lipid oversupply to insulin resistance in both beta cells and peripheral insulin-sensitive tissues [15].

The Gut Microbiome, Metabolic Signaling, and Obesity-Linked Diabetes

Among the environmental contacts modulated by lifestyle, diet emerges as a main interaction between adiposity and diabetes [16]. Gut flora composition and metabolic output are therefore altered by various physical, socioeconomic, and genetic factors [12]. Classically, metabolic health is surveyed indirectly through blood indicators of lipid accumulation, energy storage, or insulin secretion [17]. In a more direct manner, food intake informs the amount of substrate available for conversion into energy and storage. Microbiome-related mechanisms span the host, bacteria, and microbial derivatives in a tripartite network, thereby extending the link between diet and adiposity to insulin resistance and beta-cell stress [18].

Neural and Hormonal Regulation of Appetite, Energy Expenditure, and Glucose Homeostasis

Feeding behavior and glucose homeostasis are regulated by central and peripheral signals that communicate nutrient availability and energy requirements to the brain [16]. Despite the inherent differences between energy

metabolism and glucose metabolism, these two systems maintain extensive interconnections through neural circuits that ultimately modulate both energy balance and glucose homeostasis [19]. Energy balance is governed by opposite actions of two mutually inhibitory neuronal populations within hypothalamic or hindbrain nuclei. One population promotes feeding and reduces energy expenditure while the other suppresses feeding and increases energy expenditure. These neuronal circuits are modulated by a number of hormones and signals [15]. Leptin from adipose tissue and ghrelin from the stomach represent the two opposing signals acting on these hypothalamic circuits. The gut hormone GLP-1 is also involved in controlling energy balance, although its secretion is mainly triggered by food intake [12]. The actions of leptin, ghrelin, and GLP-1 on energy balance thus affect glucose homeostasis indirectly through circuits that regulate energy expenditure and feeding. Orexigenic input from these circuits, for instance, promotes hepatic glucose production and reduces glucose uptake in peripheral tissues. Correct functioning of these circuits is crucial for maintaining both energy and glucose homeostasis, as dysregulation is associated with metabolic disorders such as obesity-linked type 2 diabetes [11].

Genetic, Epigenetic, and Developmental Determinants

Obesity and type 2 diabetes (T2DM) are both conditions in which metabolic dysregulation within the body leads to the increasing prevalence of chronic diseases and decreased life expectancy [17]. It has been shown that the genetic predisposition to obesity and T2DM plays an important role in influencing the susceptibility to these metabolic conditions [18]. Numerous whole genome association studies have been performed to identify genetic variants that are associated with obesity and T2DM. Multiple genetic loci have been identified across populations that contain variants associated with increased risk for obesity and T2DM [19]. Epigenetic modifications include DNA methylation and histone variations that can be heritable and can influence the susceptibility to metabolic disease in response to environmental factors. Developing during pre- and perinatal periods, the epigenetic progress continues until reaching the post-puberty stage. Epigenetic factors can mediate the effects of environmental nutrition and stress during early life in predicting future metabolic disorders [20].

Translational Perspectives: From Mechanistic Insights to Intervention Strategies

Despite the establishment of strong and well-supported mechanistic links between excess adiposity and impaired glucose metabolism, the plethora of translational intervention strategies targeting obesity directly or indirectly to prevent or delay the onset of type 2 diabetes (T2D) remains limited and piecemeal[22]. At a core level, the basis for intervention remains rooted in the mechanistic understanding outlined previously. Although some of the obesity-associated mechanisms discussed already and elucidated further in this section are targeted specifically, other strategies acting through different modes of action yet maintaining the objective of managing excessive fat gain have the potential to interrupt the self-perpetuating cycle of adiposity and metabolic dysfunction [20, 21]. Given the difficulties in achieving sustained weight loss, novel strategies that do not rely on weight reduction, such as maintaining lipid and/or glucose flux below established specific thresholds, have gained traction [22-25]. Whether targeting only one metabolic pathway or peripherally influencing the driving mechanisms of increased adiposity, interventions that return diseased tissues toward less-obese status underscore the multi-organ and multi-factorial nature of the underlying problem[26-28]. A common challenge for all approaches, however, remains the identification of pertinent biomarkers for mechanistic monitoring in both preclinical and clinical trials, which in turn allows targeted interventions across different settings to be aligned more intelligently with fundamental understanding [29, 30].

CONCLUSION

Obesity and type 2 diabetes are tightly linked through multifaceted mechanisms involving adipose tissue dysfunction, chronic inflammation, ectopic lipid deposition, β-cell stress, mitochondrial impairment, and altered gut–brain–metabolic signaling. Adipose tissue acts as an endocrine organ, releasing bioactive molecules that modulate systemic metabolism, while genetic, epigenetic, and developmental factors influence individual susceptibility. The heterogeneity of obesity-related metabolic disturbances underscores the need for personalized interventions targeting specific molecular and cellular pathways. Translational strategies should focus on restoring metabolic homeostasis, improving β-cell function, and modulating systemic inflammation, with or without substantial weight reduction. Future studies are required to identify reliable mechanistic biomarkers, clarify inter-organ communication, and develop therapeutics that interrupt the pathophysiological cycle linking obesity to T2D. A deeper mechanistic understanding will enhance prevention, guide precision interventions, and ultimately reduce the global burden of obesity-related diabetes.

REFERENCES

1. Martínez-Montoro JI, Damas-Fuentes M, Fernández-García JC, Tinahones FJ. Role of the gut microbiome in beta cell and adipose tissue crosstalk: A review. Frontiers in Endocrinology. 2022 May 12;13:869951.
2. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat?. BMC medicine. 2014 Aug 26;12(1):123.

3. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare systems: Addressing medicine and public health challenges in conflict zones. Medicine. 2025 Feb 14;104(7):e41535.
4. Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus—An overview. International journal of molecular sciences. 2024 Feb 4;25(3):1882.
5. Cohen P, Spiegelman BM. Cell biology of fat storage. Molecular biology of the cell. 2016 Aug 15;27(16):2523-7.
6. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. Medicine. 2024 Jul 12;103(28):e38834.
7. Lee E, Nam JO. Anti-Obesity and Anti-Diabetic Effects of Ostericum koreanum (Ganghwal) Extract. International Journal of Molecular Sciences. 2024 Apr 30;25(9):4908.
8. Czech MP. Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Molecular metabolism. 2020 Apr 1;34:27-42.
9. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. Medicine. 2025 Jan 17;104(3):e41279.
10. Orliaguet L, Ejlalmanesh T, Alzaid F. Metabolic and molecular mechanisms of macrophage polarisation and adipose tissue insulin resistance. International Journal of Molecular Sciences. 2020 Aug 10;21(16):5731.
11. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. Medicine. 2025 May 2;104(18):e42289.
12. Lu J, Zhao J, Meng H, Zhang X. Adipose tissue-resident immune cells in obesity and type 2 diabetes. Frontiers in immunology. 2019 May 22;10:1173.
13. Nicholas DA, Zhang K, Hung C, Glasgow S, Aruni AW, Unternaehrer J, Payne KJ, Langridge WH, De Leon M. Palmitic acid is a toll-like receptor 4 ligand that induces human dendritic cell secretion of IL-1β. PloS one. 2017 May 2;12(5):e0176793.
14. Paul-Chima UO, Ugwu CN, Alum EU. Integrated approaches in nutraceutical delivery systems: optimizing ADME dynamics for enhanced therapeutic potency and clinical impact. RPS Pharmacy and Pharmacology Reports. 2024 Oct;3(4):rqae024.
15. Wu S, Tan J, Zhang H, Hou DX, He J. Tissue-specific mechanisms of fat metabolism that focus on insulin actions. Journal of Advanced Research. 2023 Nov 1;53:187-98.
16. Iwabu M, Okada-Iwabu M, Yamauchi T, Kadowaki T. Adiponectin/AdipoR research and its implications for lifestyle-related diseases. Frontiers in cardiovascular medicine. 2019 Aug 14;6:116.
17. Kim J, Oh CM, Kim H. The interplay of adipokines and pancreatic beta cells in metabolic regulation and diabetes. Biomedicines. 2023 Sep 21;11(9):2589.
18. Ugwu OP, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: A policy commentary from urban African populations. Obesity Medicine. 2025 Sep 1;57:100641.
19. Inaishi J, Saisho Y. Beta-cell mass in obesity and type 2 diabetes, and its relation to pancreas fat: a mini-review. Nutrients. 2020 Dec 16;12(12):3846.
20. Chiurazzi M, Di Maro M, Cozzolino M, Colantuoni A. Mitochondrial dynamics and microglia as new targets in metabolism regulation. International Journal of Molecular Sciences. 2020 May 13;21(10):3450.
21. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. Medical Hypotheses. 2025 Sep 28:111776.
22. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients. 2013 Mar 12;5(3):829-51.
23. Li X, Watanabe K, Kimura I. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. Frontiers in immunology. 2017 Dec 20;8:1882.
24. Cani PD, Everard A. Talking microbes: when gut bacteria interact with diet and host organs. Molecular nutrition & food research. 2016 Jan;60(1):58-66.
25. Alum E, PC U, Obeagu E, Aja P, Ugwu C, Okon M. Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. 11, 16–15 (2023) [Internet].

26. Roh E, Song DK, Kim MS. Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Experimental & molecular medicine. 2016 Mar;48(3):e216-.
27. Islam Mohamed Ibrahim H. Epigenetic Regulation of Obesity-Associated Type 2 Diabetes. 2022. ncbi.nlm.nih.gov
28. Lai M, Chandrasekera PC, Barnard ND. You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes. Nutrition & diabetes. 2014 Sep;4(9):e135-
29. Nneoma UC, Fabian O, Valentine EH, Paul-Chima UO. Innovations in Renewable Energy for Health Applications. system. 2025;1:2.
30. Johnson M, Jones R, Freeman C, Woods HB, Gillett M, Goyder E, Payne N. Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence. Diabetic medicine. 2013 Jan;30(1):3-15.

CITE AS: Wambui Kibibi J. (2026). Diabetes and Obesity: Mechanistic Insights. IDOSR JOURNAL OF APPLIED SCIENCES 11(1):83-88. https://doi.org/10.59298/IDOSRJAS/2026/1118388